Literature DB >> 9858422

Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation.

A Ceponis1, Y T Konttinen, M Takagi, J W Xu, T Sorsa, M Matucci-Cerinic, S Santavirta, H C Bankl, P Valent.   

Abstract

OBJECTIVE: Stem cell factor (SCF), the ligand for the SCF receptor (c-kit) expressed on precursors and mature mast cells (MC), is a major agonist for human MC (e.g., SCF induces MC development, chemotaxis, activation, proliferation of MC precursors, mediates MC adhesion, and changes MC releasability). We investigated expression of SCF and c-kit in synovial membrane with particular reference to the mechanism of local MC hyperplasia and inflammation in arthritis.
METHODS: We conducted single and double labeling immunohistochemistry (ABC, APAAP, indirect immunofluorescence techniques) with antibodies to SCF, c-kit, MC tryptase, Ki-67 antigen (marker for proliferating cells), and CD68 (monocyte/macrophage marker). Synovial specimens analyzed were from 31 patients: traumatic arthritis (TrA, n=9), osteoarthritis (OA, n=12), and rheumatoid arthritis (RA, n=10). Control experiments were performed on human lung, skin, and buccal mucosa tissues, on the HMC-1 mast cell line, and isolated lung MC. Morphometry was performed by computerized image analysis.
RESULTS: Synovial c-kit expression was found to be restricted to MC, whereas SCF is detected in synovial lining cells, stromal fibroblasts, monocyte/macrophages, endothelial cells, and in vascular basement membranes. SCF staining was localized to MC as well, but it was not possible to specify whether this represents SCF produced by or bound (via c-kit) to MC. In inflamed synovial membranes/areas, SCF was found to be redistributed into the extracellular matrix. Redistribution of SCF was accompanied by degranulation and/or accumulation of c-kit+ MC, the hyperplasia of which correlated positively with histologic inflammation/inflammatory cell densities, but did not appear to involve MC proliferation in situ. These findings appeared to be common for all the conditions (TrA, OA, RA) studied.
CONCLUSION: In addition to the demonstration/characterization of SCF and c-kit protein expression in human synovium, results of this study suggest the hypothesis that, in arthritis, local mobilization of SCF may play a role in the development of synovial MC hyperplasia without inducing in situ proliferation of MC, and that the synovial SCF/MC c-kit system may contribute to the local nonspecific inflammatory response/arthritic flares in TrA, OA, and RA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858422

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  13 in total

1.  Oral administration of high molecular weight hyaluronan (900 kDa) controls immune system via Toll-like receptor 4 in the intestinal epithelium.

Authors:  Akira Asari; Tomoyuki Kanemitsu; Hitoshi Kurihara
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

Review 2.  Tyrosine kinases as targets for the treatment of rheumatoid arthritis.

Authors:  Christina D'Aura Swanson; Ricardo T Paniagua; Tamsin M Lindstrom; William H Robinson
Journal:  Nat Rev Rheumatol       Date:  2009-06       Impact factor: 20.543

3.  Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis.

Authors:  A Juurikivi; C Sandler; K A Lindstedt; P T Kovanen; T Juutilainen; M J Leskinen; T Mäki; K K Eklund
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

4.  Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients.

Authors:  N Olsson; A K Ulfgren; G Nilsson
Journal:  Ann Rheum Dis       Date:  2001-03       Impact factor: 19.103

5.  Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes.

Authors:  Kichul Shin; Peter A Nigrovic; James Crish; Eric Boilard; H Patrick McNeil; Katherine S Larabee; Roberto Adachi; Michael F Gurish; Reuben Gobezie; Richard L Stevens; David M Lee
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

6.  The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice.

Authors:  N Shiota; P T Kovanen; K K Eklund; N Shibata; K Shimoura; T Niibayashi; C Shimbori; H Okunishi
Journal:  Br J Pharmacol       Date:  2010-01-08       Impact factor: 8.739

Review 7.  Focal bone involvement in inflammatory arthritis: the role of IL17.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti
Journal:  Rheumatol Int       Date:  2015-10-31       Impact factor: 2.631

8.  Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Authors:  Jacques Tebib; Xavier Mariette; Pierre Bourgeois; René-Marc Flipo; Philippe Gaudin; Xavier Le Loët; Paul Gineste; Laurent Guy; Colin D Mansfield; Alain Moussy; Patrice Dubreuil; Olivier Hermine; Jean Sibilia
Journal:  Arthritis Res Ther       Date:  2009-06-23       Impact factor: 5.156

9.  Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling.

Authors:  Lopamudra Das Roy; Jennifer M Curry; Mahnaz Sahraei; Dahlia M Besmer; Amritha Kidiyoor; Helen E Gruber; Pinku Mukherjee
Journal:  Breast Cancer Res       Date:  2013-04-11       Impact factor: 6.466

Review 10.  Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky.

Authors:  Jim Middleton; Laure Americh; Regis Gayon; Denis Julien; Luc Aguilar; Francois Amalric; Jean-Philippe Girard
Journal:  Arthritis Res Ther       Date:  2004-03-08       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.